Hematopoiesis News Volume 3.15 | Apr 17 2012

    0
    22

    Hematopoiesis News 3.15, April 17, 2012
    Hematopoiesis News
         In this issue: Publications | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  Hematopoiesis News on Twitter

    TOP STORY

    Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia
    Results provide improved understanding of microenvironmental regulation of normal and leukemic long-term hematopoietic stem cells and their response to imatinib in chronic myelogenous leukemia. [Cancer Cell] Abstract | Press Release

    Hematopoietic Course for Cord Blood - Learn More and Register

    PUBLICATIONS (Ranked by Impact Factor of the Journal)

    LABORATORY RESEARCH

    Connexin-43 in the Osteogenic BM Niche Regulates Its Cellular Composition and the Bidirectional Traffic of Hematopoietic Stem Cells and Progenitors
    To elucidate the biologic function of connexin-43 (Cx43) in a hematopoietic microenvironment and its influence in hematopoietic stem cell activity, researchers studied the hematopoietic function in an in vivo model of constitutive deficiency of Cx43 in osteoblasts and osteogenic progenitors. [Blood] Abstract

    Spry1 As a Novel Regulator of Erythropoiesis, EPO/EPOR Target, and Supressor of Jak2
    Studies implicate Spry1 as a novel regulator of erythropoiesis during anemia, transducer of erythropoietin receptor (EPOR) signals and candidate suppressor of Jak2 activity. [Blood] Abstract

    Heme-Regulated eIF2α Kinase Activated Atf4 Signaling Pathway in Oxidative Stress and Erythropoiesis
    Scientists report the role of the heme-regulated eIF2α kinase-activated Atf4 signaling pathway in reducing oxidative stress and in promoting erythroid differentiation during erythropoiesis. [Blood] Abstract

    In Vivo Suppression of HIV by Antigen Specific T Cells Derived from Engineered Hematopoietic Stem Cells
    Researchers sought to genetically manipulate human hematopoietic stem cells such that they differentiate into mature cytotoxic T lymphocytes that will kill HIV infected cells. [PLoS Pathog] Abstract | Press Release

    Lipid Raft Redistribution and Morphological Cell Polarization Are Separable Processes Providing a Basis for Hematopoietic Stem and Progenitor Cell Migration
    Scientists addressed impacts of protein synthesis, hematopoietic stem and progenitor cells (HSPC) trafficking, cytoskeleton organization or lipid raft integrity on the establishment and maintenance of the cell polarity of human HSPCs. [Int J Biochem Cell Biol] Abstract

    Stromal-Derived IL-6 Alters the Balance of Myeloerythroid Progenitors during Toxoplasma gondii Infection
    Data suggest that bone marrow stromal cells regulate the hematopoietic changes during inflammation via IL-6. [J Leukoc Biol] Abstract

    Efficient Commitment to Functional CD34+ Progenitor Cells from Human Bone Marrow Mesenchymal Stem-Cell-Derived Induced Pluripotent Stem Cells
    Researchers propose that CD34+ progenitor cells, which retain hematopoietic and endothelial cell potential, could be efficiently obtained from induced pluripotent stem cells derived from human bone marrow mesenchymal stem cells with defined factors. [PLoS One] Abstract

    Deferasirox Exposure Induces Reactive Oxygen Species and Reduces Growth and Viability of Myelodysplastic Hematopoietic Progenitors
    The effect of deferasirox on CD34+ hematopoietic progenitors from myelodysplastic syndrome patients was examined. [Leuk Res] Abstract

    Rapamycin Enhances Dimethyl Sulfoxide-Mediated Growth Arrest in Human Myelogenous Leukemia Cells
    Scientists tested for the possible beneficial effects of the combination of rapamycin and dimethyl sulfoxide on growth arrest and differentiation of acute myelogenous leukemia cells. [Leuk Lymphoma] Abstract

    CLINICAL RESEARCH

    High Activity of Sorafenib in FLT3-ITD-Positive Acute Myeloid Leukemia (AML) Synergizes with Allo-Immune Effects to Induce Sustained Responses
    Researchers evaluated sorafenib monotherapy in 65 FLT3-ITD-postive AML patients treated at 23 centers. [Leukemia] Abstract

    Gene Immunotherapy of Chronic Lymphocytic Leukemia: A Phase I Study of Intranodally Injected Adenovirus Expressing a Chimeric CD154 Molecule
    The results of a first-in-man Phase I trial of intranodal direct injection of adenovirus encoding chimeric CD154 in patients with chronic lymphocytic leukemia to evaluate toxicity, safety, and tolerability are reported. [Cancer Res] Abstract

    Watch the Webinar: How Three Chimerism Groups Saved Time, Effort, and Money with RoboSep

    INDUSTRY NEWS

    VistaGen Licenses Breakthrough Stem Cell Culture Technology to Speed Development of Drug Screening and Cell Therapy for Immune System Disorders
    VistaGen Therapeutics, Inc. has licensed breakthrough stem cell culture technology from the McEwen Centre for Regenerative Medicine. VistaGen will be utilizing the licensed technology to develop hematopoietic precursor stem cells from human pluripotent stem cells, with the goal of developing drug screening and cell therapy applications for human blood system disorders. [VistaGen Therapeutics, Inc.] Press Release

    Seattle Genetics and Millennium to Collaborate with Ventana on Companion Diagnostic for ADCETRIS(TM) in CD30-Positive Malignancies
    Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company announced that they have formed a collaboration with Ventana Medical Systems, Inc. (Ventana). [Seattle Genetics, Inc.] Press Release

    Cyclacel Pharmaceuticals Announces Grant of New U.S. Patent Covering Sapacitabine
    Cyclacel Pharmaceuticals, Inc. announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,124,593 which grants claims to a specified method of administration of sapacitabine with patent exclusivity until July 2030. [Cyclacel Pharmaceuticals, Inc.] Press Release

    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)
     
    Center for Biologics Evaluation and Research (United States)
     
    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

    EVENTS
    NEW ISEH – Society for Hematology and Stem Cells: 41st Annual Scientific Meeting
    August 23-26, 2012
    Amsterdam, Netherlands

    Visit our events page to see a complete list of events in the hematopoietic community

    JOB OPPORTUNITIES

    Scientist – Endothelial Cells (STEMCELL Technologies, Inc.)

    Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies Inc.)

    Scientist – hPSC Bioengineering (STEMCELL Technologies Inc.)

    Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies Inc.)

    Scientist – Epithelial Cell Research (STEMCELL Technologies Inc.)

    Scientist – Hematology (STEMCELL Technologies Inc.)

    Scientist – hPSC (STEMCELL Technologies Inc.)

    Business Analyst – Product Management (STEMSOFT Software Inc.)

    Principal Investigators in Cancer Research (Institut de Recherches Cliniques de Montréal)

    Postdoctoral Fellow in Stem Cells and Cancer (Tsinghua University)

    Recruit Top Talent
    Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

    Jobs are categorized regionally: United States, Canada, Europe, Middle East to Asia Pacific

    Visit here to post your career opportunities.

    Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

    Comments or Suggestions? Email info@connexoncreative.com with your feedback.

    Learn more about Hematopoiesis Cell News: Archives | Events | Contact Us